[ad_1]
As investors watch with concern the backlog of key deals for the European stimulus package and the failure of the pharmaceutical company Gilead’s test, stocks in Europe and Asia are losing ground.
The largest stock exchanges in the world are having a day of losses today Friday, while the concerns about the delay in some details of the stimulus package in Europe and the failure of clinical trials of treatment for Covid-19 Gilead was working around the money tables.
In this environment, the main wheels fall in a block. In Europe, the biggest contractions are seen in Spain, where the Madrid Ibex is giving up 1.30% at the moment, while the English FTSE 100, the French CAC and the German DAX record losses of 0.69%, 0.61% and 0.92%, respectively.
All in all, the pan-European benchmark EuroStoxx 50 loses 0.73% of its value at the moment.
Asia experienced a similar day: at the close, the Japanese Nikkei and the Chinese CSI 300 posted losses of 0.86% and the Hong Kong Hang Seng contracted 0.61%.
In the first operations of the day, Wall Street shows mixed results. While the industrial Dow Jones rose 0.13% and the S&P 500 appreciated 0.29%, the Nasdaq compound lost 0.22%, less than an hour from the opening.
The Santiago Stock Exchange woke up with the news of the judicial reorganization process of Enjoy, one of the companies hardest hit by the health crisis in the country. Currently, the papers of the firm linked to the Martínez family and the Advent fund operate without change at $ 13.14. For its part, the S&P IPSA indicator records a decrease of 0.62%, which has it at 3,725.26 putnos at this time.
Yesterday the leaders of the European Union decided to build an emergency fund of one trillion (million million) euros, to help the economies of the bloc to alleviate the effects of the pandemic, but discussion of more specific details was postponed of the plan, which raised investors’ anxieties.
Furthermore, on the front lines of the fight against respiratory disease, global capitals were disappointed when the potential treatment for the Covid-19 in which the company Gilead is working No functionOr in his first clinical trial, so hopes of controlling the disease on that side are also fading for now.
->
